Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study

Samy Suissa (Montreal, Canada), Samy Suissa, Sophie Dell’Aniello, Pierre Ernst

Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Session: Novel avenues in the treatment of COPD II
Session type: Thematic Poster
Number: 4084
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Samy Suissa (Montreal, Canada), Samy Suissa, Sophie Dell’Aniello, Pierre Ernst. Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study. Eur Respir J 2016; 48: Suppl. 60, 4084

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016


One-year mortality associated with COPD treatment: A comparison of tiotropium and long-acting beta-2-agonists
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014


The DACCORD study: Real-life COPD outpatient treatment with long-acting bronchodilators in Germany
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013

Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015

Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015


Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014


Long-term inhaled corticosteroid use in COPD and the risk of fracture in men and women
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016


Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS)
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014


Association between inhaled corticosteroid use in COPD and incidence or worsening of type2 diabetes
Source: International Congress 2014 – Markers
Year: 2014


Statin use and risk of exacerbations in individuals with COPD: The Copenhagen general population study
Source: International Congress 2014 – New insights into the epidemiology of COPD
Year: 2014

Safety of tiotropium in patients with cardiac events in the TIOSPIR™ trial
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015

The clinical impact of long-acting bronchodilators in newly diagnosed COPD patients
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Prescribing patterns for UK patients commencing first maintenance therapy for COPD
Source: International Congress 2014 – COPD markers
Year: 2014


Characteristics of patients newly prescribed a long acting bronchodilator in the US
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013

Safety of tiotropium in patients with cardiac events in the UPLIFT® trial
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013